A kill switch for epilepsy? China cuts seizures by 92.6% in first human chemogenetic trial
A first-in-human chemogenetic trial in China reduced seizures by 92.6% in a patient with refractory epilepsy, according to the trial's reported results. The approach uses a chemogenetic system to suppress abnormal neural…